<code id='8320C75A57'></code><style id='8320C75A57'></style>
    • <acronym id='8320C75A57'></acronym>
      <center id='8320C75A57'><center id='8320C75A57'><tfoot id='8320C75A57'></tfoot></center><abbr id='8320C75A57'><dir id='8320C75A57'><tfoot id='8320C75A57'></tfoot><noframes id='8320C75A57'>

    • <optgroup id='8320C75A57'><strike id='8320C75A57'><sup id='8320C75A57'></sup></strike><code id='8320C75A57'></code></optgroup>
        1. <b id='8320C75A57'><label id='8320C75A57'><select id='8320C75A57'><dt id='8320C75A57'><span id='8320C75A57'></span></dt></select></label></b><u id='8320C75A57'></u>
          <i id='8320C75A57'><strike id='8320C75A57'><tt id='8320C75A57'><pre id='8320C75A57'></pre></tt></strike></i>

          Home / fashion / fashion

          fashion


          fashion

          author:leisure time    Page View:7
          Eli Lilly headquarters
          Kristoffer Tripplaar/AP

          Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

          It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

          advertisement

          At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In